99 related articles for article (PubMed ID: 17050779)
1. Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody.
Goda K; Fenyvesi F; Bacsó Z; Nagy H; Márián T; Megyeri A; Krasznai Z; Juhász I; Vecsernyés M; Szabó G
J Pharmacol Exp Ther; 2007 Jan; 320(1):81-8. PubMed ID: 17050779
[TBL] [Abstract][Full Text] [Related]
2. Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG.
Krasznai ZT; Tóth A; Mikecz P; Fodor Z; Szabó G; Galuska L; Hernádi Z; Goda K
Eur J Pharm Sci; 2010 Dec; 41(5):665-9. PubMed ID: 20869436
[TBL] [Abstract][Full Text] [Related]
3. The strong in vivo anti-tumor effect of the UIC2 monoclonal antibody is the combined result of Pgp inhibition and antibody dependent cell-mediated cytotoxicity.
Szalóki G; Krasznai ZT; Tóth Á; Vízkeleti L; Szöllősi AG; Trencsényi G; Lajtos I; Juhász I; Krasznai Z; Márián T; Balázs M; Szabó G; Goda K
PLoS One; 2014; 9(9):e107875. PubMed ID: 25238617
[TBL] [Abstract][Full Text] [Related]
4. Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Nagy H; Goda K; Fenyvesi F; Bacsó Z; Szilasi M; Kappelmayer J; Lustyik G; Cianfriglia M; Szabó G
Biochem Biophys Res Commun; 2004 Mar; 315(4):942-9. PubMed ID: 14985103
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4.
Hochman JH; Chiba M; Yamazaki M; Tang C; Lin JH
J Pharmacol Exp Ther; 2001 Jul; 298(1):323-30. PubMed ID: 11408558
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein-mediated colchicine resistance in different cell lines correlates with the effects of colchicine on P-glycoprotein conformation.
Druley TE; Stein WD; Ruth A; Roninson IB
Biochemistry; 2001 Apr; 40(14):4323-31. PubMed ID: 11284688
[TBL] [Abstract][Full Text] [Related]
7. Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833.
Liminga G; Nygren P; Larsson R
Exp Cell Res; 1994 Jun; 212(2):291-6. PubMed ID: 7910563
[TBL] [Abstract][Full Text] [Related]
8. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
Jachez B; Loor F
Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
[TBL] [Abstract][Full Text] [Related]
9. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
Jiang XR; Kelsey SM; Wu YL; Newland AC
Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
[TBL] [Abstract][Full Text] [Related]
10. Analysis of P-glycoprotein-mediated membrane transport in human peripheral blood lymphocytes using the UIC2 shift assay.
Park SW; Lomri N; Simeoni LA; Fruehauf JP; Mechetner E
Cytometry A; 2003 Jun; 53(2):67-78. PubMed ID: 12766968
[TBL] [Abstract][Full Text] [Related]
11. P-Glycoprotein conformational changes detected by antibody competition.
Nagy H; Goda K; Arceci R; Cianfriglia M; Mechetner E; Szabó G
Eur J Biochem; 2001 Apr; 268(8):2416-20. PubMed ID: 11298761
[TBL] [Abstract][Full Text] [Related]
12. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.
Mechetner EB; Roninson IB
Proc Natl Acad Sci U S A; 1992 Jul; 89(13):5824-8. PubMed ID: 1352877
[TBL] [Abstract][Full Text] [Related]
13. Effects of ATP depletion and phosphate analogues on P-glycoprotein conformation in live cells.
Goda K; Nagy H; Mechetner E; Cianfriglia M; Szabó G
Eur J Biochem; 2002 Jun; 269(11):2672-7. PubMed ID: 12047375
[TBL] [Abstract][Full Text] [Related]
14. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay.
Tiberghien F; Loor F
Anticancer Drugs; 1996 Jul; 7(5):568-78. PubMed ID: 8862725
[TBL] [Abstract][Full Text] [Related]
15. Cholesterol-dependent conformational changes of P-glycoprotein are detected by the 15D3 monoclonal antibody.
Gutay-Tóth Z; Fenyvesi F; Bársony O; Szente L; Goda K; Szabó G; Bacsó Z
Biochim Biophys Acta; 2016 Mar; 1861(3):188-95. PubMed ID: 26704667
[TBL] [Abstract][Full Text] [Related]
16. Coordinate changes in drug resistance and drug-induced conformational transitions in altered-function mutants of the multidrug transporter P-glycoprotein.
Ruth A; Stein WD; Rose E; Roninson IB
Biochemistry; 2001 Apr; 40(14):4332-9. PubMed ID: 11284689
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter.
Loor F; Tiberghien F; Wenandy T; Didier A; Traber R
J Med Chem; 2002 Oct; 45(21):4598-612. PubMed ID: 12361387
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of the reversal activity of SDZ PSC833 on multi-drug resistance by an anti-P-glycoprotein monoclonal antibody MRK-16.
Naito M; Watanabe T; Tsuge H; Koyama T; Oh-hara T; Tsuruo T
Int J Cancer; 1996 Jul; 67(3):435-40. PubMed ID: 8707421
[TBL] [Abstract][Full Text] [Related]
19. The extracellular loop between TM5 and TM6 of P-glycoprotein is required for reactivity with monoclonal antibody UIC2.
Zhou Y; Gottesman MM; Pastan I
Arch Biochem Biophys; 1999 Jul; 367(1):74-80. PubMed ID: 10375401
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of flow cytometry for multidrug resistance detection in low resistance K562 cells using daunorubicin and monoclonal antibodies.
Van Acker KL; Van Hove LM; Boogaerts MA
Cytometry; 1993 Oct; 14(7):736-46. PubMed ID: 7902231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
